

From: Do, Yu  
Sent: Thursday, August 06, 2015 5:05 PM  
To: dmyers@malvernconsultinggroup.com  
Subject: Information Request: Original BLA, BL 125590/0, Immune Globulin Intravenous (RI-002), ADMA Biologics, Inc.

Dear Ms. Myers:

We are reviewing your original July 31, 2015 submission to BLA 125590/0 for Immune Globulin Intravenous (Human) and will be issuing an Acknowledgement Letter in the near future. In the meantime, we determined that the following information is necessary to continue our review:

1. The Form FDA 356h indicates in field 31 that this application contains nonclinical pharmacology and toxicology section. However, such section, which should be organized under Module 4 Folder, is not included in the submission.

Please provide explanation for the discrepancy.

The review of this submission is ongoing and issues may be added, expanded upon, or modified as we continue to review this submission. Please submit your response as an amendment to this file by August 10, 2015, referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

If we determine that your response to this information request constitutes a major amendment, we will notify you in writing.

The action due date for this file is July 30, 2016.

Please acknowledge receipt of this request and contact me at (240) 402-8343 or Yu.Do@fda.hhs.gov if you have any questions.

Sincerely,

Yu Do, M.S.  
Regulatory Project Manager  
FDA/OMPT/CBER/OBRR/IOD/RPMS  
(240) 402-8343  
yu.do@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."